Ascendis Pharma A (ASND) Other financing activities (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Other financing activities data on file, last reported at $37.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities rose 154.44% year-over-year to $37.0 million; the trailing twelve-month figure through Mar 2026 stood at $122.1 million (up 394.92% YoY), and the FY2025 full-year result was $101.4 million, up 206.91% from the prior year.
• Other financing activities climbed to $37.0 million in Q1 2026, from $17.9 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $53.1 million in Q3 2025 to a low of $226496.3 in Q2 2023.
• A 5-year average of $11.0 million and a median of $3.2 million in 2024 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities plunged 90.47% in 2022 and surged 3490.58% in 2025, its largest moves.
• Tracing ASND's Other financing activities over 5 years: stood at $3.2 million in 2022, then plunged by 32.01% to $2.2 million in 2023, then jumped by 49.32% to $3.2 million in 2024, then soared by 451.16% to $17.9 million in 2025, then soared by 107.2% to $37.0 million in 2026.
• Business Quant data shows ASND's Other financing activities at $37.0 million in Q1 2026, $17.9 million in Q4 2025, and $53.1 million in Q3 2025.